RxDoctor Payments Data

Amanda El-Sawaf

Gerontology · Nashville, TNNPI 1922699370

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Medtronic at 40.9% of the total.

$794in general payments, 2019–2025

Across 21 payments — averaging $37.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$324
  • Amgen$142
  • Philips North America LLC$140
  • Boehringer Ingelheim$94
  • W. L. Gore & Associates, Inc.$50
  • Terumo Medical Corporation$31
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$74494%
  • Education$506%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794 in reported general payments places this provider in the 65th percentile of 194 gerontology providers in Tennessee.

See all gerontology providers in Tennessee

Medicare billing

Part B allowed, 2024
$35,089
Medicare patients
231
Services billed
425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$116,602
EntrestoSacubitril/Valsartan57$68,441
XareltoRivaroxaban38$35,731
JardianceEmpagliflozin29$35,694
Repatha SyringeEvolocumab13$9,369
Rosuvastatin Calcium271$2,295
Metoprolol Succinate124$1,232
Atorvastatin Calcium154$1,109
Amlodipine Besylate119$941
Olmesartan Medoxomil58$939
Spironolactone77$636
ClopidogrelClopidogrel Bisulfate48$601
Hydralazine Hcl33$591
Losartan Potassium48$521
Ezetimibe46$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$94$35,69429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 194 gerontology providers in Tennessee.

Other gerontology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →